Relmada Therapeutics To Report Third Quarter 2026 Financial Results On Thursday, November 12, 2026
Conference Call and Webcast Information:
- Date: Thursday, November 12, 2026 at 4:30 PM ET Participant Dial-in (US): 1-800-717-1738 Participant Dial-in (International): 1-646-307-1865 Webcast Access: Click Here
A replay of the webcast will be available in the Investors section of the Relmada website at .
About Relmada Therapeutics, Inc.
Relmada Therapeutics is a clinical-stage biotechnology company focused on developing transformative therapies for oncology and central nervous system conditions. Its lead candidates, NDV-01 and sepranolone, are advancing through clinical development with the potential to address significant unmet needs.
For more information, visit
Investor Contact:
Brian Ritchie
LifeSci Advisors
...
Media Inquiries:
Corporate Communications
...
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Comments
No comment